About 200 reports

  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H1 2018
  • HEART TRANSPLANT REJECTION - PIPELINE BY NOXXON PHARMA AG, H1 2018

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Blood Disease
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • Target
  • Target

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* HEART TRANSPLANT REJECTION

  • Autoimmune Disease
  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • Vaccine
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018 (CONTD..1), H2 2018

Of the remaining two patients, one received a bone marrow transplant after achieving CR and one discontinued due to Grade ## colitis.

  • Autoimmune Disease
  • Blood Disease
  • Research And Development
  • Targeted Therapy
  • Vaccine

Transplant Organ Rehabilitation: Dr.

  • Autoimmune Disease
  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • Vaccine
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019

Report covers products from therapy areas Immunology, Oncology, Infectious Disease and Metabolic Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Rheumatoid Arthritis, Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflamma

  • Autoimmune Disease
  • Blood Disease
  • Hospital
  • Therapy
  • Vaccine
  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018 (CONTD..1), H1 2018

The cases reported that were determined not to be study drug related involve one case of brain injury following trauma ## days after discontinuation of study drug; one case of worsening of RA ## days after discontinuation of study drug; and one case of acute

  • Autoimmune Disease
  • Blood Disease
  • Targeted Therapy
  • Therapy
  • Vaccine

WE ARE FULFILLING OUR PROMISE TO MAKE SEQUENCING BASED INFORMATION AVAILABLE TO THE TRANSPLANT CLINIC, NOW ALSO FOR HEART TRANSPLANT PATIENTS. "

  • Blood Disease
  • Orthopedics
  • Vaccine
  • Canada
  • North America
  • PIPELINE BY ASTELLAS PHARMA INC, H2 2018
  • Human Immunodeficiency Virus (HIV) Infections (AIDS)

Report covers products from therapy areas Immunology, Oncology, Infectious Disease, Metabolic Disorders and Undisclosed which include indications Rheumatoid Arthritis, Autoimmune Disorders, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ewing Sarcoma, Heart Transplant Reject

  • Autoimmune Disease
  • Blood Disease
  • Hospital
  • Therapy
  • Vaccine
  • PIPELINE BY ASTELLAS PHARMA INC, H1 2018
  • Autoimmune Disorders

Report covers products from therapy areas Immunology, Oncology, Infectious Disease, Metabolic Disorders and Undisclosed which include indications Rheumatoid Arthritis, Human Immunodeficiency Virus (HIV) Infections (AIDS), Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Reject

  • Autoimmune Disease
  • Hospital
  • Vaccine
  • World
  • Product Initiative

Liver transplant replaces an injured or diseased liver with a healthy one.

  • Autoimmune Disease
  • Blood Disease
  • General Medicine And Specialty Medicine
  • Targeted Therapy
  • Vaccine

Food and Drug Administration (FDA), World Health Organization (WHO), GLOBOCAN, and various organ transplant registries.

  • Blood Disease
  • Hospital
  • Orthopedics
  • United States
  • Zimmer Biomet Holdings, Inc.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Blood Disease
  • Targeted Therapy
  • Vaccine
  • World
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Autoimmune Disease
  • Blood Disease
  • Immunotherapy
  • Targeted Therapy
  • Vaccine

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Autoimmune Disease
  • Blood Disease
  • Immunotherapy
  • Targeted Therapy
  • Vaccine

WE ARE ALSO EXCITED ABOUT THE DEMONSTRATED VALUE OF OUR IL-## PLATFORM IN CARDIAC DISEASE.

  • Autoimmune Disease
  • Blood Disease
  • Endometrial Cancer
  • Targeted Therapy
  • Vaccine
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

GVHD is a condition that can occur after an allogeneic transplant (the transfer of genetically dissimilar blood stem cells) and is a significant cause of morbidity and mortality in transplant recipients.

  • Autoimmune Disease
  • Blood Disease
  • Endometrial Cancer
  • Targeted Therapy
  • Vaccine
  • 5. All the trials included are unique trials.

P. A. ", Italy) GDCT## GDC##, MFM## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lupus Nephritis, Transplant Rejection Completed Phase I Interventional

  • Autoimmune Disease
  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • Vaccine

Patients will be randomized in a ##:##:## fashion to placebo or one of two different doses of AG## on a background of stable heart failure therapy.

  • Autoimmune Disease
  • Blood Disease
  • Endocrine Disease
  • Targeted Therapy
  • Vaccine

Liver transplant replaces an injured or diseased liver with a healthy one.

  • Autoimmune Disease
  • Digestive System Disorder
  • Targeted Therapy
  • Vaccine
  • United States

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Blood Disease
  • Targeted Therapy
  • Vaccine
  • Conatus Pharmaceuticals Inc.
  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Autoimmune Disease
  • Blood Disease
  • Targeted Therapy
  • Vaccine
  • Product Initiative

CLINICAL TRIALS BY PHASE IN G## COUNTRIES LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINIC

  • Autoimmune Disease
  • Blood Disease
  • Targeted Therapy
  • Vaccine
  • Novartis AG
  • RECOMBINANT PROTEINS TO ANTAGONIZE IFN-GAMMA RECEPTOR 1 FOR ALOPECIA AREATA AND GRAFT ARTERIOSCLEROSIS - DRUG PROFILE
  • RECOMBINANT PROTEINS TO ANTAGONIZE IFN-GAMMA RECEPTOR 1 FOR ALOPECIA AREATA AND GRAFT ARTERIOSCLEROSIS - DRUG PROFILE

One patient who achieved a CR went on to transplant.

  • Autoimmune Disease
  • Blood Disease
  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • Vaccine
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Blood Disease
  • Neurological Disorder
  • Targeted Therapy
  • Vaccine
  • DORMANT PRODUCTS, H2 2019 (CONTD..1), H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019 (CONTD..4), H2 2019

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Autoimmune Disease
  • Blood Disease
  • Immunotherapy
  • Targeted Therapy
  • Vaccine
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Autoimmune Disease
  • Blood Disease
  • Targeted Therapy
  • Vaccine
  • World
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..4), H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

MP## is currently in phase ##.

  • Autoimmune Disease
  • Blood Disease
  • Immunotherapy
  • Targeted Therapy
  • Vaccine
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • Vaccine

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Blood Disease
  • Drug Development
  • Targeted Therapy
  • Vaccine